



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

|                                |   |       |
|--------------------------------|---|-------|
| <b>Summary for ARTG Entry:</b> | 334455  | SB 5B |
| <b>ARTG entry for</b>          | Medicine Listed                               |       |
| <b>Sponsor</b>                 | Natural Bio Pty Limited                       |       |
| <b>Postal Address</b>          | PO Box 384, MONA VALE, NSW, 1660<br>Australia |       |
| <b>ARTG Start Date</b>         | 17/04/2020                                    |       |
| <b>Product Category</b>        | Medicine                                      |       |
| <b>Status</b>                  | Active  |       |
| <b>Approval Area</b>           | Listed Medicines                              |       |

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . SB 5B

|                     |                         |                       |            |
|---------------------|-------------------------|-----------------------|------------|
| <b>Product Type</b> | Single Medicine Product | <b>Effective Date</b> | 22/11/2022 |
|---------------------|-------------------------|-----------------------|------------|

### Permitted Indications

Maintain/support general health and wellbeing  
Decrease/reduce/relieve diarrhoea  
Helps reduce occurrence of diarrhoea  
Helps reduce occurrence of symptoms of traveller's diarrhoea  
Relief of symptoms of medically diagnosed Irritable Bowel Syndrome  
Maintain/support digestive system health  
Maintain/support healthy immune system function  
Maintain/support healthy gastrointestinal immune function

### Indication Requirements

Label statement: If symptoms persist or worsen talk to your medical practitioner.

Label statement: Seek medical advice if diarrhoea persists for more than: 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3 to 6 years or 48 hours in adults and children over 6 years (or words to that effect).

Product presentation must not imply or refer to serious immunological diseases.

Product presentation must only refer to medically diagnosed IBS.

### Standard Indications

No Standard Indications included on Record

### Specific Indications

No Specific Indications included on Record

### Warnings

If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years, seek medical advice (or words to that effect).

If symptoms persist consult your healthcare practitioner (or words to that effect).

### Additional Product information

Public Summary



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration

| Pack Size/Poison information         |                 |
|--------------------------------------|-----------------|
| Pack Size                            | Poison Schedule |
| Components                           |                 |
| 1 . Formulation 1                    |                 |
| Dosage Form                          | Capsule, hard   |
| Route of Administration              | Oral            |
| Visual Identification                |                 |
| Active Ingredients                   |                 |
| Saccharomyces cerevisiae (Boulardii) | 250 mg          |
| Other Ingredients (Excipients)       |                 |
| calcium hydrogen phosphate dihydrate |                 |
| carrageenan                          |                 |
| colloidal anhydrous silica           |                 |
| hypromellose                         |                 |
| iron oxide yellow                    |                 |
| magnesium stearate                   |                 |
| microcrystalline cellulose           |                 |
| potassium acetate                    |                 |
| purified water                       |                 |
| sorbitan monostearate                |                 |
| titanium dioxide                     |                 |

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary